Cediranib: Difference between revisions

Cediranib
Clinical data
Routes of; administration	Oral
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
	IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;
CompTox Dashboard (EPA)	DTXSID10183035 ;
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.505 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc4nc5ccc(Oc3ncnc2cc(OCCCN1CCCC1)c(OC)cc23)c(F)c5c4;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 17:14, 17 May 2009

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.^[1]^[2]^[3]

It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.

On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

References

^ Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Goss G, Shepherd FA, Laurie S; et al. (2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45: 782. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Nikolinakos P, Heymach JV (2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296. {{cite journal}}: Unknown parameter |month= ignored (help)

External links

AZD2171—AstraZeneca Pipeline

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[pmid15899831-1] Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[pmid19091548-2] Goss G, Shepherd FA, Laurie S; et al. (2008). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group". Eur. J. Cancer. 45: 782. doi:10.1016/j.ejca.2008.10.022. PMID 19091548. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[pmid18520296-3] Nikolinakos P, Heymach JV (2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". J Thorac Oncol. 3 (6 Suppl 2): S131–4. doi:10.1097/JTO.0b013e318174e910. PMID 18520296. {{cite journal}}: Unknown parameter |month= ignored (help)

[1]

[2]

[3]

@@ Line 25: / Line 25: @@
 | routes_of_administration = Oral
 }}
-'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref><ref name="pmid19091548">{{cite journal |author=Goss G, Shepherd FA, Laurie S, ''et al'' |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=Eur. J. Cancer |volume= 45|issue= |pages= 782|year=2008 |month=December |pmid=19091548 |doi=10.1016/j.ejca.2008.10.022 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X}}</ref><ref name="pmid18520296">{{cite journal |author=Nikolinakos P, Heymach JV |title=The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies |journal=J Thorac Oncol |volume=3 |issue=6 Suppl 2 |pages=S131–4 |year=2008 |month=June |pmid=18520296 |doi=10.1097/JTO.0b013e318174e910 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910}}</ref>
+'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al.'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref><ref name="pmid19091548">{{cite journal |author=Goss G, Shepherd FA, Laurie S, ''et al.'' |title=A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group |journal=Eur. J. Cancer |volume= 45|issue= |pages= 782|year=2008 |month=December |pmid=19091548 |doi=10.1016/j.ejca.2008.10.022 |url=http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(08)00868-X}}</ref><ref name="pmid18520296">{{cite journal |author=Nikolinakos P, Heymach JV |title=The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies |journal=J Thorac Oncol |volume=3 |issue=6 Suppl 2 |pages=S131–4 |year=2008 |month=June |pmid=18520296 |doi=10.1097/JTO.0b013e318174e910 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?doi=10.1097/JTO.0b013e318174e910}}</ref>
 It is being developed by [[AstraZeneca]] as a possible anti-cancer chemotherapeutic agent for oral administration.
@@ Line 31: / Line 31: @@
 Beginning in 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
-On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
+On February 27, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
 ==References==
@@ Line 41: / Line 41: @@
 {{Extracellular chemotherapeutic agents}}
-{{pharma-stub}}
 [[Category:Tyrosine kinase inhibitors]]
 [[Category:Indoles]]
 [[Category:Quinazolines]]
+{{pharma-stub}}